within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AG02_Delavirdine;

model Delavirdine
  extends Pharmacolibrary.Drugs.ATC.J.J05AG02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AG02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as part of combination antiretroviral therapy for the treatment of HIV-1 infection. Its clinical use has largely diminished in favor of newer agents due to lower efficacy and higher rates of drug interactions; it is no longer recommended in current treatment guidelines and is not widely used or available today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in HIV-infected adult patients after single and multiple oral doses. Main data from clinical trials, studies include both male and female adults with HIV infection.</p><h4>References</h4><ol><li><p>Smith, PF, et al., &amp; Morse, GD (2005). Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. <i>Clinical pharmacokinetics</i> 44(1) 99–109. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544010-00004&quot;>10.2165/00003088-200544010-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15634033/&quot;>https://pubmed.ncbi.nlm.nih.gov/15634033</a></p></li><li><p>Cheng, CL, et al., &amp; Stetson, PL (1997). Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. <i>Clinical pharmacology and therapeutics</i> 61(5) 531–543. DOI:<a href=&quot;https://doi.org/10.1016/S0009-9236(97)90133-8&quot;>10.1016/S0009-9236(97)90133-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9164415/&quot;>https://pubmed.ncbi.nlm.nih.gov/9164415</a></p></li><li><p>Morse, GD, et al., &amp; Freimuth, WW (2003). Effect of Food on the Steady-State Pharmacokinetics of Delavirdine in Patients with HIV Infection. <i>Clinical drug investigation</i> 23(4) 255–261. DOI:<a href=&quot;https://doi.org/10.2165/00044011-200323040-00005&quot;>10.2165/00044011-200323040-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17535038/&quot;>https://pubmed.ncbi.nlm.nih.gov/17535038</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Delavirdine;
